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OBJECTIVES The goal of this study was to determine whether the level of kidney function is an
independent risk factor for atherosclerotic cardiovascular disease (ASCVD) outcomes in the
Atherosclerosis Risk in Communities (ARIC) study, a prospective cohort study of subjects
aged 45 to 64 years.
BACKGROUND The level of kidney function is now recognized as a risk factor for ASCVD outcomes in
patients at high risk for ASCVD, but it remains unknown whether the level of kidney
function is a risk factor for ASCVD outcomes in the community.
METHODS Cox proportional-hazards regression was used to evaluate the association of glomerular
filtration rate (GFR) with ASCVD after adjustment for the major ASCVD risk factors in
15,350 subjects. We searched for nonlinear relationships between GFR and ASCVD.
RESULTS During a mean follow-up time of 6.2 years, 965 (6.3%) of subjects had ASCVD events.
Subjects with GFR of 15 to 59 ml/min/1.73 m2 (n 444, hazard ratio 1.38 [1.02, 1.87]) and
60 to 89 ml/min/1.73 m2 (n  7,665, hazard ratio 1.16 [1.00, 1.34]) had an increased
adjusted risk of ASCVD compared with subjects with GFR of 90 to 150 ml/min/1.73 m2.
Each 10 ml/min/1.73 m2 lower GFR was associated with an adjusted hazard ratio of 1.05
(1.02, 1.09), 1.07 (1.01, 1.12), and 1.06 (0.99, 1.13) for ASCVD, de novo ASCVD, and
recurrent ASCVD, respectively. A nonlinear model did not fit the data better than a linear
model.
CONCLUSIONS The level of GFR is an independent risk factor for ASCVD and de novo ASCVD in the
ARIC study. (J Am Coll Cardiol 2003;41:47–55) © 2003 by the American College of
Cardiology Foundation
It has recently been recognized that a decreased level of
kidney function is an independent risk factor for all-cause
mortality as well as adverse cardiovascular disease (CVD)
outcomes including myocardial infarction, stroke, and pro-
gression of heart failure (1–4). This risk has, in particular,
been noted in subjects who already have some form of CVD
(1–3) or in subjects at high risk for the development of
CVD (4).
There is conflicting data, however, as to whether the level
of kidney function is an independent risk factor for CVD
outcomes in a community cohort of subjects who were not
selected for being at high risk for CVD. The level of kidney
function was not found to be a risk factor for CVD outcomes
in the Framingham cohort (5) or for CVD death in the
National Health and Nutrition Examination Survey
(NHANES) I (6), but was found to be a risk factor for CVD
death in an analysis of the NHANES II (7).
In the current analysis, we evaluated the relationship
between level of kidney function and atherosclerotic CVD
(ASCVD) in the Atherosclerosis Risk in Communities
(ARIC) Study. Although data from ARIC are limited by
the absence of urinalyses, the current analysis overcomes
many of the limitations of prior studies that have assessed
the relationship between level of kidney function and CVD
outcomes by estimating kidney function both as a continu-
ous as well as a categorical variable, evaluating both de novo
and recurrent ASCVD, and using estimated glomerular
filtration rate (GFR) rather than serum creatinine to assess
level of kidney function. We also explore the possibility of
nonlinear relationships between GFR and the risk of
ASCVD, and search for potential interactions between level
of kidney function and traditional CVD risk factors.
METHODS
Design. ARIC is a community-based longitudinal study of
coronary heart disease (CHD) and stroke in persons ages 45
to 64 years. A total of 15,792 study participants were
recruited from the city of Jackson, Mississippi; Forsyth
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County, North Carolina; the northwestern suburbs of Min-
neapolis, Minnesota; and Washington County, Maryland.
There is an extensive follow-up for ascertainment of
ASCVD events (defined by myocardial infarction, cardiac
procedure, CHD death, and stroke). Details of recruitment
and the study have been extensively described elsewhere (8).
The present study is a secondary analysis of the ARIC
public use data to ascertain the relationship of baseline
kidney function to ASCVD outcomes.
Ascertainment of the level of kidney function. Serum
creatinine was measured using the modified kinetic Jaffe
method in 15,582 subjects at baseline. Level of GFR is
usually regarded as the best overall index of the level of
kidney function because serum creatinine is determined by a
number of factors other than GFR, such as gender, age,
muscle mass, and ethnicity. Glomerular filtration rate was,
therefore, estimated using a formula developed and vali-
dated in the Modification of Diet in Renal Disease
(MDRD) study (9,10) as follows:
GFR  186.3  (serum creatinine1.154)  (age0.203)
 1.212 if black  0.742 if female [1]
Serum creatinine is measured in mg/dl, age in years, and
GFR is expressed as ml/min/1.73 m2. Because serum
creatinine values may vary between different labs, and in
order to more accurately use the formula developed in the
MDRD study, we indirectly calibrated ARIC serum creat-
inine values to the Cleveland Clinic Laboratory (where
serum creatinine was measured in the MDRD study) by
using NHANES III data. Because both NHANES III and
ARIC were designed as representative samples of the
population, and NHANES III data have been directly
compared with the MDRD samples (11), it was assumed
that the mean serum creatinine for a given age, gender, and
race should be comparable in the two studies. A linear
regression of data combining the two studies showed that
serum creatinine levels were 0.24 mg/dl higher among
ARIC participants during the baseline examination than
among NHANES III participants after adjustment for age,
gender, and race and limiting the analysis to individuals age
45 to 65 years who were white or black and had a serum
creatinine2.0 mg/dl at baseline. This value was subtracted
from serum creatinine before application of the MDRD
equation (as shown earlier) in order to obtain a more valid
estimate of GFR.
Our objective was to evaluate the association of kidney
function with ASCVD in subjects with GFR between 15 to
150 ml/min/1.73 m2. We chose this range for two reasons.
First, a GFR of 15 ml/min/1.73 m2 is defined as kidney
failure in the National Kidney Foundation (NKF) Kidney
Disease Outcomes Quality Initiative (K/DOQI) guidelines
(12). A total of 20 subjects had estimated GFR values 15
ml/min/1.73 m2. Second, a GFR of 150 ml/min/1.73 m2 is
approximately the upper limit of most normal GFR mea-
surements in this age group (2 SD above the mean) (13),
and values above this range (n  212 [1.4%] of ARIC
participants) are potentially less accurate estimates of level of
kidney function. The study population, therefore, included
15,350 subjects (15,582  20  212).
Baseline variables. Baseline characteristics included demo-
graphics (age, ethnicity, gender, and educational level);
lifestyle (smoking, alcohol intake, and exercise intensity);
past medical history (baseline ASCVD, diabetes mellitus,
hypertension, left ventricular hypertrophy [LVH] defined
by voltage in AVL being 11 mm by electrocardiogram);
laboratory variables (albumin, creatinine, total cholesterol,
high-density lipoprotein [HDL] cholesterol, low-density
lipoprotein [LDL] cholesterol, triglycerides, fibrinogen, uric
acid, and hematocrit); physical examination (weight, body
mass index, waist-to-hip ratio, systolic and diastolic blood
pressure); and medication use as grouped in the public use
database (vasodilating agents, cardiac agents, aspirin/
nonsteroidals, lipid-lowering agents, and diuretics). Of
note, 4% of subjects in ARIC were receiving angiotensin-
converting enzyme inhibitors at baseline (14). Urinalyses
were not performed in ARIC. The methods employed by
the ARIC investigators for the surveillance and ascertain-
ment of ASCVD events have been described elsewhere (15).
Outcomes. We evaluated four outcomes: 1) ASCVD, 2)
de novo ASCVD (defined as an ASCVD event in subjects
without ASCVD at baseline), 3) recurrent ASCVD (de-
fined as ASCVD in patients with baseline ASCVD), and 4)
all-cause mortality.
For de novo disease, because there were missing baseline
data on cerebrovascular disease in 3,093 subjects, we per-
formed analyses both by using the data available as well as
using multiple imputation techniques for missing data (16).
For all-cause mortality, we present the data as the propor-
tion of deaths in the groups stratified by level of kidney
function.
Statistical analysis. Means, SD, and percentages were used
to describe the baseline characteristics. Data were stratified
into three groups by level of kidney function, namely, GFR
of 15 to 59 ml/min/1.73 m2, 60 to 89 ml/min/1.73 m2, and
GFR of 90 to 150 ml/min/1.73 m2. These cut-points were
chosen as an estimated GFR of 90 ml/min/1.73 m2 or
Abbreviations and Acronyms
ARIC  Atherosclerosis Risk in Communities Study
ASCVD  atherosclerotic cardiovascular disease
CHD  coronary heart disease
CVD  cardiovascular disease
GFR  glomerular filtration rate
HDL  high-density lipoprotein
K/DOQI  Kidney Disease Outcomes Quality
Initiative
LDL  low-density lipoprotein
LVH  left ventricular hypertrophy
MDRD  Modification of Diet in Renal Disease
NHANES  National Health and Nutrition
Examination Survey
NKF  National Kidney Foundation
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greater represents a normal GFR at any age, while a GFR of
60 to 89 ml/min/1.73 m2 represents a mild decrease in
GFR, and a GFR of 15 to 59 ml/min/1.73 m2 represents a
moderate to severe decrease in GFR as defined by the NKF
K/DOQI guidelines (12). We did not include a separate
group with GFR between 15 to 30 ml/min/1.73 m2 as only
12 subjects had GFR within this range. Chi-squared tests
and the analysis of variance were used to compare baseline
data between these groups.
Kaplan-Meier survival analysis was used to compare
survival time among the three groups stratified by level of
kidney function. The log-rank statistic was used to test for
differences between groups. Cox proportional hazards re-
gression was used to adjust for covariates. Multivariable
stepwise selection models were constructed and estimated
GFR modeled as a continuous variable and as a categorical
variable, with the cut-points as described above. All analyses
adjusted for traditional CVD risk factors as defined in the
Framingham population, including age, gender, smoking
status, diabetes, systolic blood pressure, total cholesterol,
HDL and LDL cholesterol, and LVH by electrocardio-
gram, as well as baseline variables that were significantly and
independently related to ASCVD, de novo ASCVD, and
recurrent ASCVD in univariate analyses (p  0.05). The
proportional hazard assumption was tested using a time-
varying coefficient model testing for global and individual
covariates.
We then repeated the above analyses first by including
patients with GFR 150 ml/min/1.73 m2 and second by
using serum creatinine (rather than estimated GFR) as the
continuous variable of interest. These additional analyses
were performed primarily to confirm the internal consis-
tency of our results.
We then performed analyses to define the best form of
the relationship between level of kidney function and
ASCVD. Curvilinear associations of GFR were tested by
including a quadratic term and retaining it when significant
(p 0.05), and by fitting parametric smoothing splines with
five knots (at 0.05, 0.275, 0.5, 0.725, 0.95 quantiles of
GFR) to determine the functional form of GFR that best
explained its relationship to ASCVD. The results were
displayed by graphing the five-year predicted probability of
ASCVD versus GFR. Because the prediction for each
individual includes their 19 baseline covariates, it is consid-
ered unadjusted. Adjusted predicted probabilities at a given
GFR were obtained by assuming all cohort members had
this given GFR (for example 60 ml/min/1.73 m2) and
calculating the average five-year predicted probability across
the entire cohort (17). Values were calculated in 5 ml/min/
1.73 m2 increments and the results graphed versus GFR
using a smoothing function. Adjusted values for a linear
model and a cubic spline model were compared graphically
to each other and the unadjusted risk.
We tested for interactions between estimated GFR and
traditional ASCVD risk factors with ASCVD as the out-
come of interest.
Data was analyzed using the SAS version 8.1 (SAS
Institute, Cary, North Carolina). S-Plus (MathSoft, Seattle,
Washington) was used to explore nonlinear associations in
these models. Testing was two sided, and p values 0.05
were considered statistically significant.
RESULTS
Baseline characteristics. The baseline characteristics of
the 15,350 subjects are given in Table 1. The baseline serum
creatinine was 1.1 mg/dl with a range of 1.0 to 5.0 mg/dl,
and the baseline estimated GFR was 92 ml/min/1.73 m2
with a range of 16 to 149 ml/min/1.73 m2. The mean age
was 54.2 years, and 45% and 26% were men and African
Americans, respectively. A total of 5% and 4.8% of the
subjects had CHD and cerebrovascular disease at baseline,
respectively.
Association of reduced kidney function with other base-
line factors. A total of 444 individuals (2.8%) had a GFR
of 15 to 59 ml/min/1.73 m2 with the mean GFR being 52.3
ml/min/1.73 m2. A total of 7,665 individuals (49.9%) had a
GFR of 60 to 89 ml/min/1.73 m2 with the mean GFR
being 79.3 ml/min/1.73 m2.
The prevalence of baseline ASCVD and risk factors for
ASCVD tended to be higher in the group with lower
baseline GFR (Table 1). For example, subjects with lower
GFR had a higher prevalence of CHD, cerebrovascular
disease, diabetes mellitus, and hypertension, as well as
higher mean serum total cholesterol, LDL cholesterol, and
triglycerides.
Outcomes. The maximum duration of follow-up in the
public use data was 8.1 years with a mean follow-up of 6.2
years. There were 775 (5%) deaths (Table 2). A total of 174
(22.4%) of the deaths were directly attributable to ASCVD.
A total of 965 (6.3%) of subjects experienced ASCVD
events. Of these events, 767 (79.4%) were due to CHD, and
198 (20.6%) were due to cerebrovascular disease.
Kaplan-Meier survival analysis showed a greater proba-
bility of ASCVD (p  0.001), de novo ASCVD (p 
0.001), and recurrent ASCVD (p  0.02) events and
all-cause mortality (p  0.001) in subjects with lower GFR
(Figs. 1 and 2, Table 2).
Multivariable models. After adjusting for traditional AS-
CVD risk factors as well as variables significant in univariate
analysis in the Cox proportional hazards models, the hazard
ratios for ASCVD and de novo ASCVD were significantly
higher in subjects with GFR of 15 to 59 ml/min/1.73 m2
and GFR of 60 to 89 ml/min/1.73 m2 compared with
subjects with GFR of 90 to 150 ml/min/1.73 m2 (the
reference group) (Table 3). Similar results were obtained
when subjects with estimated GFRs 150 ml/min/1.73 m2
were included in the analyses.
Expressing GFR as a continuous variable, and after
adjusting for traditional ASCVD risk factors as well as
variables significant in univariate analysis in the Cox pro-
portional hazards models, GFR remained a significant risk
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factor for ASCVD and de novo ASCVD and showed a
trend towards being a risk factor for recurrent ASCVD
(Table 3). That is, a 10 ml/min/1.73 m2 lower GFR was
associated with an adjusted hazard ratio of 1.05 (1.02, 1.09),
1.07 (1.01, 1.12), and 1.06 (0.99, 1.13), for total ASCVD,
de novo ASCVD, and recurrent ASCVD, respectively.
The results were essentially identical when subjects with
estimated GFRs 150 ml/min/1.73 m2 were included in
the analyses. For example, for every 10 ml/min/1.73 m2
lower estimated GFR, the hazard ratio for ASCVD was
1.05 (1.02, 1.09; p  0.002).
When serum creatinine was used as the primary
measure of level of kidney function, each 0.1 mg/dl
increase in serum creatinine was associated with a 1.04
(1.01, 1.07; p  0.003) increase in hazard ratio for
development of ASCVD.
The test for assumption of proportional hazards was met
for ASCVD, de novo ASCVD, and recurrent ASCVD. For
the de novo analysis, data using multiple imputation tech-
niques (for cerebrovascular disease prevalence) showed sim-
ilar results to that using the data available.
Nonlinear associations with ASCVD. The five-year
probability of ASCVD events as a function of baseline GFR
is shown in Figure 2. Without adjustment for covariates, the
Table 1. Baseline Characteristics of Study Population
Baseline Variables
GFR 15–150 (Total)
ml/min/1.73 m2
(N  15,350)
92  18.9
GFR 15–59
ml/min/1.73 m2
(N  444)
52.3  7.9
GFR 60–89
ml/min/1.73 m2
(N  7,665)
79.3  7.6
GFR 90–150
ml/min/1.73 m2
(N  7,241)
108  13.1
p
Value
Demographic data
Age (yrs) 54.2  5.7 56.7  5.8 54.6  5.6 53.6  5.8  0.001
Male 45.2 37.2 47.0 43.8  0.001
African American 25.9 22.3 15.1 37.6  0.001
Education (high school and lower) 44.0 37.8 45.6 42.6  0.001
Physical characteristics
Weight (kgs) 78.7  16.6 80.3  16.1 78.9  16.3 78.5  16.9 0.03
Waist/hip ratio 0.93  0.1 0.94  0.1 0.93  0.1 0.92  0.1 0.001
Body mass index 27.7  5.3 28.8  5.5 27.6  5.0 27.8  5.7 0.001
Lifestyle characteristics
Current smokers 26.0 21.2 22.0 30.6  0.001
Smoking (pack yrs) 16.1  21.8 18.7  23.5 15.2  21.2 16.9  22.3  0.001
Current drinkers 56.1 47.7 59.2 53.4 0.001
Alcohol (g/week) 42.4  95.8 25.1  58.5 39.9  85.3 46.1  107.4  0.001
Exercise (low- vs. high-intensity) 79.8 84.6 76.6 82.9 0.001
Baseline past medical history
Diabetes mellitus 11.6 24.3 9.6 12.8  0.001
Hypertension 34.6 58.0 33.6 34.3  0.001
Coronary heart disease 5.0 11.4 5.5 4.1  0.001
Cerebrovascular disease 4.8 9.8 4.9 4.4  0.001
Atherosclerotic cardiovascular disease* 9 19.1 10.0 8.2  0.001
Left ventricular hypertrophy by ECG† 4.8 4.7 4.3 5.4 0.007
Clinical exam
Systolic blood pressure (mm Hg) 121.2  18.8 125.8  22.8 120.1  18.3 122.0  18.9  0.001
Diastolic blood pressure (mm Hg) 73.66  11.2 74.07  11.6 73.19  10.8 74.13  11.6  0.001
Laboratory measurements
Albumin (mg/dl) 3.87  0.3 3.82  0.3 3.89  0.3 3.86  0.3  0.001
Creatinine (mg/dl) 1.1  0.2 1.6  0.4 1.2  0.2 1.0  0.1  0.001
Total cholesterol (mg/dl) 215.1  42.0 224.3  48.4 216.2  41.6 213.4  41.9  0.001
HDL cholesterol (mg/dl) 51.6  17.0 48.8  17.5 50.4  16.7 52.9  17.3  0.001
LDL cholesterol (mg/dl) 137.9  39.3 145.0  44.2 139.4  39.0 135.8  39.1  0.001
Triglycerides (mg/dl) 131.6  89.3 160.6  111.1 134.6  87.4 126.7  89.3  0.001
Fibrinogen (mg/dl) 303.2  65.0 331.8  77.7 299.4  63.2 305.4  65.4  0.001
Uric acid (mg/dl) 6.1  1.6 7.4  2.0 6.2  1.5 5.8  1.5  0.001
Hematocrit (%) 41.7  4.0 40.8  4.8 42.1  3.9 41.4  4.0  0.001
Medications:
Vasodilating agents 3.8 11.5 3.9 3.2  0.001
Diuretics 17.4 42.3 17.3 16.0  0.001
Cardiac agents‡ 12.5 28.4 13.9 10.1  0.001
Aspirin/nonsteroidals 40.6 49.8 42.8 37.7  0.001
Lipid-lowering medications 1.3 2.5 1.6 0.9  0.001
Continuous variables are presented as mean  SD while categorical variables are expressed as percent. P values are for the analysis of variance for continuous and chi-square for
categorical variables for differences between glomerular filtration rate (GFR) groups (columns 3, 4, and 5). *Atherosclerotic cardiovascular disease is a composite of coronary disease
and cerebrovascular disease; †Left ventricular hypertrophy (LVH) defined by voltage in AVL being 11 mm by electrocardiogram (ECG); ‡Cardiac agents not including
vasodilator agents, diuretics, aspirin/nonsteroidals, or lipid-lowering medications.
HDL  high-density lipoprotein; LDL  low-density lipoprotein.
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probability of developing ASCVD increases markedly below
a GFR of approximately 75 ml/min/1.73 m2. After adjust-
ment for covariates, the effect of GFR on ASCVD is
diminished but remains present. For example, the five-year
probability of ASCVD increases from approximately 4% to
6% with a decrease in GFR from 150 ml/min/1.73 m2 to 30
ml/min/1.73 m2. The nonparametric smoothing method led
us to explore both linear and piecewise linear forms for
GFR. The quadratic term was not significant. A GFR value
of 78 ml/min/1.73 m2 was found to be the optimum knot
point of a two-slope model based on maximizing the log
likelihood. The resulting two-slope model (relative hazard
of 1.03 for every 10 ml/min/1.73 m2 decrease in GFR above
78 ml/min/1.73 m2, and 1.11 for every 10 ml/min/1.73 m2
decrease in GFR above 78 ml/min/1.73 m2) was not,
however, statistically better than a one-slope linear model.
Figure 2 is consistent with the latter in that it demonstrates
the similarity between the adjusted cubic spline with one
knot and linear models.
Interactions. There was a significant interaction between
GFR and the presence of LVH. That is, in subjects with
LVH, a 10 ml/min/1.73 m2 lower GFR was associated with
a hazard ratio of 1.19 for ASCVD, while in subjects without
LVH, the hazard ratio was 1.03 (p for the interaction
0.007). This interaction was also present in exclusively de
novo ASCVD (p  0.013). We noted a trend towards an
interaction (p 0.08) between GFR and race with regard to
ASCVD outcomes (a decreased GFR being a stronger risk
factor in African Americans than whites). There was no
significant interaction between level of kidney function
measured as a continuous variable (and using a linear
model), with age, gender, presence of diabetes mellitus,
systolic and diastolic blood pressure, smoking, and LDL
and HDL cholesterol for ASCVD outcomes.
DISCUSSION
Kidney function declines by approximately 10 ml/min/1.73
m2 per decade, even in the absence of chronic kidney
disease. Normal GFR in young adults is approximately 90 to
125 ml/min/1.73 m2. Recently published clinical practice
guidelines by the NKF define a GFR 60 ml/min/1.73 m2
for three months or more as chronic kidney disease (12).
Individuals with GFR 60 to 89 ml/min/1.73 m2 do not have
chronic kidney disease unless there is also a marker of
kidney damage, for example, proteinuria.
Our results demonstrate that a lower level of kidney
function is associated with a marked increase in the prob-
ability of ASCVD over five years. We also found that level
of kidney function (even in the range of 60 to 89 ml/min/
1.73 m2, approximately equivalent to a calibrated creatinine
as low as 0.9 to 1.1 mg/dl in a white man of age 55) is an
independent risk factor for ASCVD and de novo ASCVD
outcomes. Finally, we noted that ASCVD risk may increase
more sharply at lower levels of GFR, but a nonlinear model
was not significantly better than a linear model.
Prior studies of patients with CVD or subjects at high
risk for CVD have generally been consistent in showing an
independent association between decreased level of kidney
function and increased CVD outcomes (1–4). Studies of
lower or intermediate-risk populations have not been con-
clusive. For example, the Hypertension Detection and
Follow-up Program (HDFP) found an association between
higher serum creatinine and CVD mortality (18), while the
Multiple Risk Factor Intervention trial (19) and the Fra-
mingham study (5) did not.
Our study demonstrates that the level of kidney function
is an independent risk factor for ASCVD outcomes in the
community. The only prior studies that we are aware of that
Table 2. All-Cause Mortality, ASCVD, De Novo ASCVD, and Recurrent ASCVD Events and Rates, Stratified by Level of
Kidney Function
GFR 15–150 (Total)
ml/min/1.73 m2
GFR 15–59
ml/min/1.73 m2
GFR 60–89
ml/min/1.73 m2
GFR 90–150
ml/min/1.73 m2
Log-Rank
p Value‡
All-cause mortality
% Events 5.0% (775/15,350) 16.7% (74/444) 4.4% (337/7,665) 5.0% (364/7,241)  0.001
Person-years at risk 95,411 2,554 47,631 45,226
Events per 1,000 person-years 8.1 29.0 7.1 7.7
ASCVD events
% Events 6.3% (965/15,350) 14.2% (63/444) 6.6% (507/7,665) 5.5% (395/7,241)  0.001
Person-years at risk 93,172 2,465 46,445 44,262
Events per 1,000 person-years 10.4 25.6 10.9 8.9
De novo ASCVD*
% Events 4.5% (471/10,420) 9.3% (26/280) 4.8% (253/5,232) 3.9% (192/4,908)  0.001
Person-years at risk 60,615 1,546 30,432 28,637
Events per 1,000 person-years 7.8 16.8 8.3 6.7
Recurrent ASCVD†
% Events 19.7% (275/1,393) 28.4% (23/81) 20.4% (151/739) 17.6% (101/573) 0.02
Person-years at risk 7,461 378 3,966 3,117
Events per 1,000 person-years 36.9 60.8 38.1 32.4
*De novo ASCVD  events in subjects without baseline ASCVD; †Recurrent ASCVD  events in subjects with baseline ASCVD; ‡p values are for the log-rank for the
Kaplan-Meier differences between GFR groups (columns 3, 4, and 5). Note: Events in subjects with de novo and recurrent ASCVD do not add up to the total ASCVD because
of subjects with missing data regarding baseline cerebrovascular status.
ASCVD  atherosclerotic cardiovascular disease, de novo ASCVD plus recurrent ASCVD; GFR  glomerular filtration rate.
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Figure 1. (A) Kaplan-Meier survival analysis for atherosclerotic cardiovascular disease (ASCVD) stratified by level of glomerular filtration rate (GFR). (B)
Kaplan-Meier survival analysis for de novo ASCVD stratified by level of GFR. (C) Kaplan-Meier survival analysis for recurrent ASCVD stratified by level
of GFR. (D) Kaplan-Meier survival analysis for all-cause mortality stratified by level of GFR.
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have evaluated the association of level of kidney function
with CVD outcomes in the community are NHANES I
and II (6,7) and the Framingham study (5). The results
from the NHANES studies gave conflicting results, with
NHANES II (7) noting an association between level of
kidney function and CVD death and NHANES I noting no
association between level of kidney function and CVD
death (6). The current analysis of the ARIC cohort adds to
those studies by having prospective standardized ASCVD
event ascertainment (8,15), rather than relying on death
certificate data as the primary outcome (6,7). In addition to
reliance on death certificate data, the lack of association in
NHANES I may at least be partly due to a small number of
events (n  197 cardiovascular deaths) and reliance on
serum creatinine rather than estimated GFR.
Culleton et al. (5) evaluated the relationship of elevated
serum creatinine, defined by serum creatinine of 1.5 to 3.0
mg/dl in men and 1.4 to 3.0 mg/dl in women, to CVD and
all-cause mortality in 6,233 subjects in the Framingham
study. Results showed that an elevated serum creatinine was
associated with a higher prevalence of CVD and CVD risk
factors at baseline. However, in multivariable analysis,
elevated serum creatinine was not independently associated
with a higher risk for CVD in either men or women.
Our results confirm the findings of Culleton et al. (5)
with regard to a higher prevalence of CVD and CVD risk
factors in patients with reduced GFR. In addition, we dem-
onstrate that the increased prevalence of CVD and CVD risk
factors likely play a major role in promoting an increased risk
for ASCVD in patients with decreased GFR (comparison
between unadjusted and adjusted models, Fig. 2).
Our results, however, differ from those of the Framing-
ham population in that we found an independent associa-
tion of level of kidney function to ASCVD outcomes. There
are two potential explanations for the differences between
our results and those of the Framingham study. First, the
ARIC cohort is larger, and although the number of events
is similar, with very long duration from measurement of
serum creatinine and no African American participants, the
Framingham study may have had lower power. We noted a
trend towards an interaction (p  0.08) between GFR and
race with regard to ASCVD outcomes, a topic worth further
study. Second, equations that estimate GFR may provide
greater power than serum creatinine alone. These equations
appropriately take into account how gender, age, and race
modify the association between creatinine and GFR. The
association between estimated GFR and ASCVD still needs
to be adjusted for age, gender, and race to avoid confound-
ing by these factors, but the analysis benefits from examin-
ing the predictive power of a much better estimate of GFR
than serum creatinine alone.
Figure 2. Smoothed five-year predicted probability of developing atherosclerotic cardiovascular disease by level of glomerular filtration rate (GFR).
Unadjusted curve shows the risk incorporating each individual’s value for 19 covariates in Table 3. Adjusted curve shows the average risk in the
Atherosclerosis Risk in Communities study population if everyone had the GFR value on the X-axis. The linear model includes GFR as a continuous
variable in a Cox regression while the cubic spline includes a cubic transition between linear segments with knots (at 0.05, 0.275, 0.5, 0.725, 0.95 quantiles
of GFR) corresponding to GFR values of 63.7, 81.7, 88.2, 101.1, and 123.7 ml/min/1.73 m2, respectively. Tick marks along the X-axis indicate GFR values
for individual participants (the marks form a solid bar in GFR regions with many individuals). A lower GFR cut-off of 30 ml/min/1.73 m2 was chosen
because only 12 subjects had GFR values between 15 and 30 ml/min/1.73 m2; therefore, the data was less precise in the latter range.
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Interactions. The significant interaction between LVH
and GFR on ASCVD outcomes is consistent with prior
studies that have demonstrated that level of kidney function
is an independent risk factor for outcomes in individuals
who already have CVD (1–4). The interaction should, how-
ever, be interpreted with caution. First, the method used to
define the presence of LVH is insensitive, and, second, the
interaction was not one of our a priori hypotheses.
Potential explanations as to why level of kidney function
may be a risk factor for outcomes. There are several
theoretical but unproven explanations as to why the level of
kidney function may be an independent risk factor for
ASCVD outcomes. First, a decrease in the level of kidney
function may be associated with increased levels of nontra-
ditional CVD risk factors, such as elevated homocysteine
levels, oxidative stress, and remnant cholesterol particles,
that were not measured in the study and, therefore, not
adjusted for in our analysis. Second, there may be residual
confounding from variables for which we have adjusted. For
example, a decrease in level of kidney function at baseline
may be a marker of the severity of prior vascular damage
(including subclinical cardiac disease) due to hypertension.
Third, reduced kidney function itself may be a risk factor for
progression of ventricular remodeling and cardiac dysfunc-
tion.
Nonlinear versus linear association of GFR with ASCVD.
Our results show that, although we were able to establish an
optimum GFR cut-point (78 ml/min/1.73 m2), a two-slope
model did not fit the data better than a one-slope linear
model. Therefore, in the ARIC study, there is no clear
threshold level of GFR above which the adjusted risk for
ASCVD is not lower at a higher GFR.
Study limitations. There are three potential limitations of
our analyses. First, recent studies have shown that albumin-
uria, an alternate marker for the presence of kidney disease,
may be an independent risk factor for CVD outcomes (20).
Unfortunately, urinalyses were not performed in ARIC, and
we, therefore, could not adjust for the presence of albumin-
uria. Second, we are unable to account for differences or
clustering of outcomes due to the center effect. This is due
to the fact that the public use database does not provide
center information because of concern of confidentiality.
Although we are unable to completely overcome this limi-
tation, we have endeavored to control for all variables that
may track with center location such as education, ethnicity,
and numerous other comorbidities. Third, indirect calibra-
tion of serum creatinine to the NHANES III study is not as
precise as a direct comparison. However, this calibration
resulted in GFR estimates that are more similar to direct
inulin measurements supporting its use.
Conclusions. The level of kidney function is an indepen-
dent risk factor for ASCVD in middle-aged subjects who
are not selected for being at higher risk for CVD.
Reprint requests and correspondence: Dr. Mark J. Sarnak, Box
391, New England Medical Center, 750 Washington Street,
Boston, Massachusetts 02111. E-mail: msarnak@lifespan.org.
Table 3. The Association of Level of Kidney Function on ASCVD, De Novo ASCVD, and Recurrent ASCVD
Outcomes
GFR Stratified Into Three Groups
Unadjusted Hazard Ratio
(95% CI) p Value
Adjusted Hazard Ratio
(95% CI) p Value
ASCVD*
15–59 ml/min/1.73 m2 2.89 (2.22, 3.77), 0.001 1.38 (1.02, 1.87), 0.038
60–89 ml/min/1.73 m2 1.22 (1.07, 1.40), 0.003 1.16 (1.00, 1.34), 0.045
90–150 ml/min/1.73 m2 1.0 (reference) 1.0 (reference)
De novo ASCVD†
15–59 ml/min/1.73 m2 2.55 (1.69, 3.84), 0.001 1.58 (1.01, 2.47), 0.047
60–89 ml/min/1.73 m2 1.24 (1.03, 1.50), 0.023 1.25 (1.02, 1.52), 0.031
90–150 ml/min/1.73 m2 1.0 (reference) 1.0 (reference)
Recurrent ASCVD‡
15–59 ml/min/1.73 m2 1.88 (1.20, 2.96), 0.006 1.53 (0.95, 2.47), 0.079
60–89 ml/min/1.73 m2 1.18 (0.92, 1.52), 0.201 1.12 (0.85, 1.48), 0.409
90–150 ml/min/1.73 m2 1.0 (reference) 1.0 (reference)
Outcomes GFR as a Continuous Variable
ASCVD* (per 10 ml/min/1.73 m2 lower GFR) 1.14 (1.10, 1.18), 0.001 1.05 (1.02, 1.09), 0.006
De novo ASCVD† (per 10 ml/min/1.73 m2 lower GFR) 1.11 (1.06, 1.17),  0.001 1.07 (1.01, 1.12), 0.015
Recurrent ASCVD‡ (per 10 ml/min/1.73 m2 lower GFR) 1.11 (1.04, 1.18), 0.001 1.06 (0.99, 1.13), 0.114
*Adjusted model with age, gender, race, baseline coronary heart disease, baseline stroke/transient ischemic attack, hypertension, diabetes mellitus, left ventricular hypertrophy by
electrocardiogram (ECG), smoking status, pack years, body mass index, waist/hip ratio, activity level, systolic blood pressure, total cholesterol, high-density lipoprotein (HDL),
cholesterol, albumin, fibrinogen, and vasodilating agents; †Adjusted model with age, gender, race, hypertension, diabetes mellitus, left ventricular hypertrophy by ECG, smoking
status, systolic blood pressure, total cholesterol, HDL cholesterol, albumin, fibrinogen, cardiac agents, vasodilating agents; ‡Adjusted model with age, gender, race, systolic blood
pressure, low-density lipoprotein cholesterol, HDL cholesterol, albumin, smoking status, vasodilating agents, cardiac agents, left ventricular hypertrophy by ECG, total
cholesterol, and diabetes.
ASCVD  atherosclerotic cardiovascular disease; CI  confidence interval; GFR  glomerular filtration rate.
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